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Abstract: Mitochondrial (m) KATP channel opening has been implicated in 
triggering cardiac preconditioning. Its consequence on mitochondrial 
respiration, however, remains unclear. We investigated the effects of two 
different KATP channel openers and antagonists on mitochondrial respiration 
under two different energetic conditions. Oxygen consumption was measured 
for complex I (pyruvate/malate) or complex II (succinate with rotenone) 
substrates in mitochondria from fresh guinea pig hearts. One of two mKATP 
channel openers, pinacidil or diazoxide, was given before adenosine 
diphosphate in the absence or presence of an mKATP channel antagonist, 
glibenclamide or 5-hydroxydecanoate. Without ATP synthase inhibition, both 
mKATP channel openers differentially attenuated mitochondrial respiration. 
Neither mKATP channel antagonist abolished these effects. When ATP synthase 
was inhibited by oligomycin to decrease [ATP], both mKATP channel openers 
accelerated respiration for both substrate groups. This was abolished by 
mKATP channel blockade. Thus, under energetically more physiological 
conditions, the main effect of mKATP channel openers on mitochondrial 
respiration is differential inhibition independent of mKATP channel opening. In 
contrast, under energetically less physiological conditions, mKATP channel 
opening can be evidenced by accelerated respiration and blockade by 
antagonists. Therefore, the effects of mKATP channel openers on mitochondrial 
function likely depend on the experimental conditions and the cell's 
underlying energetic state. 
Keywords: heart, mitochondria, cardiac preconditioning, ion channels, state, 
ischemia 
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Introduction 
Opening of mitochondrial (m) adenosine triphosphate (ATP) 
sensitive K+ channels has been postulated to be a key component of 
the signaling mechanism of ischemic and pharmacologic 
preconditioning of the myocardium.1–3 This is primarily based on 
observations that transient administration of mKATP channel openers, 
such as diazoxide, elicits a memory effect that lasts beyond their 
elimination and attenuates subsequent ischemia/reperfusion (IR) 
injury in different models. Moreover, the nonspecific KATP channel 
antagonist glibenclamide, as well as 5-hydroxydecanoic acid (5-HD), a 
putative mKATP channel antagonist, abolish ischemic and pharmacologic 
preconditioning with different agents.4–6 
In most of these studies, conclusions are derived from the 
assessment of IR injury on reperfusion and, therefore, solely rely on 
the specificity for the mKATP channel of the drugs given before 
ischemia. However, not only have these specificities recently been 
more and more questioned,7–11 there is also an ongoing debate as to 
the putative effect of mKATP channel opening on mitochondrial function 
in general. Liu et al,12 for example, argue that mKATP channel opening 
leads to accelerated electron transport and, therefore, a net oxidation 
of the mitochondrial electron transport chain (ETC); this was shown by 
increased fluorescence of oxidized flavoprotein in resting myocytes by 
the mKATP channel opener diazoxide. However, using a more 
physiological, intact beating heart model, we were unable to reproduce 
these findings; in fact, we observed decreased rather than increased 
oxidation with different known and putative mKATP channel openers.13–
15 This is supported by Garlid et al,2 who oppose the idea of mild 
uncoupling by mKATP channel opening and state that the critical effect 
of mKATP channel opening is the regulation and maintenance of 
mitochondrial matrix volume during ischemia. 
We hypothesized that these opposing results and seemingly 
mutually exclusive theories in the literature could possibly be unified 
and explained by their different underlying experimental conditions, 
that is, the energetic state of the cells and their mitochondria. The 
objective of this study was, therefore, to assess the effects of 
commonly used KATP channel openers on mitochondrial respiration, but 
under different energetic conditions within the same model. To test our 
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hypothesis, we compared the effects of different mKATP channel 
openers and blockers on the rate of O2 consumption in isolated cardiac 
mitochondria under energetically more physiological conditions versus 
those under energetically less physiological conditions produced by 
ATP synthase inhibition. 
Methods 
All investigations conformed to the Guide for the Care and Use 
of Laboratory Animals (U.S. National Institutes of Health no. 85-23, 
revised 1996) and were approved by the institutional animal care and 
use committee (Medical College of Wisconsin, Milwaukee, Wisc). Thirty 
milligrams of ketamine and 1000 units of heparin were injected 
intraperitoneally into 20 albino English short-haired guinea pigs (250–
300 g). Animals were decapitated 15 minutes later, when 
unresponsive to noxious stimulation. After thoracotomy, the heart was 
immediately taken out and immersed in 4°C cold isolation buffer15,16: 
200 mM mannitol, 50 mM sucrose, 5 mM KH2PO4, 1 mM EGTA, 5 mM 
MOPS, and 0.1% bovine serum albumin; pH 7.15 adjusted with KOH. 
The atria were discarded, and the ventricles were minced into 1-mm 
pieces. The tissue was rinsed, transferred to a glass Potter–Elvehjem 
homogenizing vessel on ice, and gently homogenized with a Teflon 
pestle (DuPont, Wilmington, Del) for 30 seconds in the presence of 1 
mg/mL of protease. This was followed by another 30 seconds of 
homogenization after 10-fold dilution of the protease. Mitochondria 
were then isolated by differential centrifugation at 4°C.17 The tissue 
suspension was centrifuged at 8000g for 10 minutes to remove the 
protease. The resulting pellet was then resuspended in 28-mL isolation 
buffer, and the suspension was centrifuged at 700g for 10 minutes to 
remove cellular debris. The supernatant containing the mitochondrial 
fraction was further centrifuged at 8000 g for 10 minutes. The pellet 
was resuspended in 7-mL isolation buffer without EGTA and was 
centrifuged at 8000 g for 10 minutes. The final mitochondrial pellet 
was resuspended in 500-μL cold isolation buffer without EGTA. Total 
protein concentration was determined18 with bovine serum albumin as 
a standard. Anatomic integrity of isolated mitochondria was verified by 
electron microscopy in random studies. 
Measurement of Mitochondrial Oxygen Consumption 
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The 500-μL mitochondrial suspension was kept at 4°C. 
Immediately before each experiment, an aliquot of the concentrated 
mitochondria was added to 27°C respiration buffer15,16,19 to yield 500 
μL with a concentration of 500 μg of protein per milliliter. The buffer 
contained 110 mM KCl, 5 mM K2HPO4 · 3H2O, 10 mM MOPS, 10 mM 
Mg-acetate, 1 mM EDTA, 1 μmM tetrasodium pyrophosphate, and 
0.1% bovine serum albumin; pH 7.15 adjusted with KOH. The low 
concentration of acetate was added to improve mitochondrial function 
and facilitate K+ transport and matrix volume adjustments.20 Although 
it may serve as a potential mitochondrial substrate,21 it does not cause 
uncoupling at this concentration.20 
Mitochondria from one heart were sufficient for approximately 
15 experiments on average. [O2] was measured polargraphically with a 
Clark-type oxygen electrode (model 1302, Strathkelvin Instruments, 
Glasgow, Scotland) in a water-jacketed 500-μl chamber (Model 
MT200A, Strathkelvin Instruments) equipped with a Teflon-coated 
magnetic stirring bar and monitored by an oxygen meter (Model 782, 
Strathkelvin Instruments). The oxygen electrode was calibrated with 
air-saturated water (pO2 ≈ 150 mm Hg) and sodium sulphite (Na2SO3) 
solution to achieve near-zero pO2 at the same temperature as the 
buffer to be used. Rate of mitochondrial respiration was determined as 
the maximum rate of [O2] decrease after addition of substrate and 
adenosine diphosphate (ADP) to initiate oxidative phosphorylation.22 
Data were stored online on a computer using the manufacturer's 
software (Strathkelvin Instruments). Microsoft Excel (Microsoft 
Corporation, Redmond, Wash) software was used for later analysis. 
Experimental Protocol 
After sealing the chamber with a plexiglass plug (time t = 0 
minutes), drugs, substrates, and ADP (5 μL each) were subsequently 
injected into the chamber according to the protocol displayed in Figure 
1. The time intervals in the experimental protocol have been 
successfully used in previous studies15,23 and were carefully chosen 
after extensive preliminary experiments to ensure sufficient time for 
each drug to exhibit its full effect. All final drug concentrations are 
provided in Table 1. To test for possible antagonism, the mKATP 
channel blocker 5-HD,4 the nonspecific KATP channel blocker 
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glibenclamide,5 or their vehicle with or without the ATP synthase 
inhibitor oligomycin (see below) were added at t = 1 minute. Pyruvate 
and malate, or succinate with the complex I blocker rotenone to 
prevent reverse electron flow,24 were added at t = 2 minutes as 
substrates for complex I or for complex II of the ETC, respectively. The 
mKATP channel opener pinacidil or diazoxide or their vehicle was added 
at t = 3 minutes to test for drug-induced alterations of mitochondrial 
respiration. In additional experiments, 2,4-dinitrophenol (DNP) as an 
uncoupler, or antimycin A as a blocker of complex III of the ETC, were 
given at t = 3 minutes to verify mitochondrial function and to assess 
the degree of maximal uncoupling and maximal blockade of 
mitochondrial respiration in our model (Fig. 2). ADP was added at t = 
4 minutes. All drugs were purchased from Sigma (St. Louis, Mo). 
Chamber [O2] in micromoles per liter was monitored for up to 12 
minutes or until it approached zero. All experiments were performed at 
27°C. Experiments with mitochondria from the same heart were 
randomized to one of the above treatment groups with at least three 
control experiments interspersed. All respiration rates from 
experiments of one heart were normalized and expressed as percent 
change compared with the average of control experiments from the 
same heart. 
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FIGURE 1 Experimental protocol. After stabilization of the mitochondrial 
suspension for 1 minute, the mitochondrial KATP channel inhibitor 5-hydroxydecanoic 
acid (5-HD), the non-specific KATP channel inhibitor glibenclamide (Glib), or their 
respective vehicle (buffer) was injected into the chamber with or without the ATP 
synthase inhibitor oligomycin (O). Substrate (Sub) for complex I (pyruvate and 
malate) or for complex II (succinate with rotenone to block complex I) was added at t 
= 2 minutes. The KATP channel openers diazoxide (DZO) or pinacidil (Pin) or their 
vehicle (dimethyl sulfoxide, DMSO) were given at t = 3 minutes. Adenosine 
diphosphate (ADP) was added at t = 4 minutes. Each drug or substrate was given as a 
5-μL bolus into the 500-μL chamber to yield the final concentrations given in Table 1. 
Chamber [O2] in micromoles was monitored for up to 12 minutes or until it 
approached zero. All experiments were performed at 27°C. 
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FIGURE 2 Original sample tracings of oxygen consumption when succinate was 
given as substrate for complex II in the presence of rotenone to block complex I. The 
complex III blocker antimycin A (AA), the uncoupler 2,4-dinitrophenol (DNP), the 
mKATP channel opener diazoxide (DZO), or vehicle (Con; plain DMSO) were given at t 
= 3 minutes (drug) before ADP was added at t = 4 minutes (dotted vertical line). Note 
the difference in slope (ie, mitochondrial respiration) after t = 4 minutes between 
blockade by antimycin A and uncoupling by DNP regardless of ADP addition. A, 
Diazoxide caused a slightly slower respiration after ADP addition compared with 
control in the absence of ATP synthase inhibition with oligomycin. B, In addition to 
control, antimycin A, DNP, and diazoxide, a tracing of the mKATP channel opener 
pinacidil (Pin) at t = 3 minutes (drug) is shown in the presence of the ATP synthase 
inhibitor oligomycin (O). Note the decreased rate of respiration in the control run 
compared with a control without (w/o) oligomycin after t = 4 minutes as well as the 
lack of a slowing of respiration secondary to complete phosphorylation of ADP to ATP 
in the absence of oligomycin after t = 5 minutes. Both pinacidil and diazoxide caused a 
slight increase in respiration compared with control after t = 4 minutes. All drug 
concentrations are listed in Table 1. 
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State 3 Versus State 4 Respiration 
Under energetically more physiological conditions, that is, in the 
absence of ATP synthase inhibition by oligomycin, addition of ADP 
initiates the transition to so-called “state 3” respiration.22 In short, the 
energy from mitochondrial electron transport along the ETC is used to 
actively pump protons against their gradient into the intermembrane 
space, which contributes to the mitochondrial membrane potential 
(Δψm) that is then used by the ATP synthase to actively phosphorylate 
ADP to ATP. Mitochondrial respiration, Δψm, and phosphorylation are 
coupled and in a steady state (↔, Table 2). When ADP is completely 
phosphorylated to ATP (so-called “state 4” respiration22), ATP synthase 
activity is decreased because of a lack of ADP as substrate. This 
increases Δψm and attenuates respiration indirectly. However, we 
chose to induce “state 4” conditions by pharmacological inhibition with 
oligomycin rather than to use regular “state 4” respiration by ADP 
depletion, because this approach allowed us to selectively block ATP 
synthase and while comparing respiration rates at the same time 
intervals under otherwise similar experimental conditions, that is, 
oxygen concentrations, equilibration times, etc. In addition, this 
approach enabled us to keep the ATP/ADP ratio low (< 0.3 in our 
model as assessed with HPLC) and, in that way, mimic an energetically 
less physiological state better than a regular “state 4” with its higher 
(>50) ATP/ADP ratio. “State 3” and the two different “state 4” 
conditions are compared in Table 2. 
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Statistical Analysis 
All data were expressed as means ± standard errors of the 
means (SEM). Group data were compared by analysis of variance to 
determine significance (Super ANOVA 1.11 software for Macintosh 
from Abacus Concepts, Berkeley, Calif). If F values (P < 0.05) were 
significant, post hoc comparisons of means tests (Student–Newman–
Keuls) were used to compare the groups. Differences among means 
were considered statistically significant when P < 0.05 (two tailed). 
Statistical symbols used were * versus Con, † versus DZO, # versus 
DZO + 5-HD, § versus DZO + Glib, and ‡ versus Pin. 
Results 
Control experiments without ATP synthase inhibition revealed 
functionally intact mitochondria with “state 3” O2 consumptions (nmol 
O2·mg−1 protein·min−1) of 107.8 ± 12.8 and 193.6 ± 12.0 and with 
respiratory control indices of 3.2 ± 0.2 and 2.4 ± 0.1 for complex I 
and complex II substrates, respectively. Original sample tracings of O2 
chamber concentrations with complex II substrate are shown in Figure 
2. Panel A depicts typical O2 tracings after addition of the complex III 
blocker antimycin A, the uncoupler DNP, or the KATP channel opener 
diazoxide compared with a control experiment without ATP synthase 
inhibition. In contrast, panel B shows antimycin A, DNP, diazoxide, and 
the KATP channel opener pinacidil compared with a control experiment 
after ATP synthase inhibition with oligomycin, and one control 
experiment without ATP synthase inhibition. 
In the absence of oligomycin to inhibit ATP synthase, the mKATP 
channel antagonists 5-HD and glibenclamide had no effect on 
respiration for either complex I or complex II substrates when given 
alone (Fig. 3A and B). Diazoxide did not alter respiration when 
complex I substrates (pyruvate and malate; panel A) were given, but 
it decreased respiration by about 10% when succinate with rotenone 
was given as a substrate for complex II (panel B). In contrast, 
pinacidil decreased respiration by about 20% when complex I 
substrates were given (panel A), but it had no effect when complex II 
substrate was given (panel B). Neither of these effects was prevented 
by mKATP channel blockade (panels A and B). In comparison, antimycin 
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A decreased respiration by 50.2 ± 3.5%* and 78.8 ± 3.5%* for 
complex I and II substrates, respectively, whereas DNP increased 
respiration by 35.6 ± 18.4%* and 28.9 ± 11.5%*, respectively. 
 
FIGURE 3 Percent change in mitochondrial respiration from control levels (Con) by 
the KATP channel openers diazoxide (DZO) and pinacidil (Pin) and by the KATP channel 
inhibitors 5-hydroxydecanoic acid (5-HD) and glibenclamide (Glib) when pyruvate and 
malate were given as substrate for complex I (panel A) or when succinate (with 
rotenone to block complex I) was given as substrate for complex II (panel B). in 
absence of the ATP synthase inhibition. All values are given as means and SEM; P < 
0.05 *versus Con, †versus DZO, #versus DZO+5-HD, §versus DZO+Glib, and ‡versus 
Pin; n = 7 experiments per experimental group. All drug concentrations are listed in 
Table 1. 
At the selected concentration, the ATP synthase inhibitor 
oligomycin attenuated, but did not completely inhibit, mitochondrial 
respiration, for both complex I and complex II substrates: control 
experiments with oligomycin exhibited a 16.0 ± 4.6%* lower 
respiration rate for pyruvate/malate and a 9.5 ± 2.8%* lower rate for 
succinate/rotenone. In the presence of the ATP synthase inhibitor, 
both KATP channel openers increased respiration for either substrate 
group by 7% to 10% (Fig. 4A and B). For complex I substrates, both 
mKATP channel antagonists reversed both KATP channel agonist–induced 
increases in respiration back to control levels (panel A). For complex II 
substrate, both mKATP channel antagonists reversed the pinacidil-
induced increase back to control levels, whereas in the presence of 
diazoxide, glibenclamide led to a decrease even below control levels 
(panel B). In comparison, DNP increased respiration by 54.5 ± 15.1%* 
and 79.7 ± 15.9%* for complex I and II substrates, respectively, 
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whereas antimycin A decreased respiration by 85.9 ± 1.6%* and 85.1 
± 1.3%*, respectively, under these conditions. 
 
FIGURE 4 Percent change in mitochondrial respiration from control levels (Con) by 
the KATP channel openers diazoxide (DZO) and pinacidil (Pin) and by the KATP channel 
inhibitors 5-hydroxydecanoic acid (5-HD) and glibenclamide (Glib) when pyruvate and 
malate were given as substrate for complex I (panel A), or when succinate (with 
rotenone to block complex I) was given as substrate for complex II (panel B). in the 
presence of the ATP synthase inhibitor oligomycin. All values are given as means and 
SEM; P < 0.05 *versus Con, †versus DZO, #versus DZO+5-HD, § versus DZO + Glib, 
and ‡versus Pin; n = 7 experiments per experimental group. All drug concentrations 
are listed in Table 1. 
Discussion 
Results from this study in isolated cardiac mitochondria indicate 
that (a) KATP channel openers produce differential effects on 
mitochondrial function, and (b) these effects depend on the 
mitochondrial energy state. Under energetically more physiological 
conditions, the KATP channel openers diazoxide and pinacidil attenuated 
mitochondrial respiration: pinacidil inhibited complex I, whereas 
diazoxide inhibited complex II. These inhibitory effects were 
independent of mKATP channel opening. In contrast, under energetically 
less physiological conditions, that is, when ATP synthase was 
pharmacologically inhibited, both KATP channel openers accelerated 
mitochondrial respiration, which seemed to be mediated by mKATP 
channel opening. 
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mKATP Channel Opening and Cardioprotection 
KATP channels were first identified in 1983 by Noma25 in 
membrane patches prepared from guinea pig myocytes. Since then, 
they have also been shown to exist in various other tissues and seem 
to consist of several subtypes. KATP channels are composed of two 
distinct proteins, an inwardly rectifying K+ channel and a sulfonylurea 
receptor, which may have a regulatory role as well as a function in 
modulating the sensitivity of the channel to ATP, other nucleotides, 
and pharmacological agonists and antagonists.26 Two types of KATP 
channels have been postulated to exist in the cell, a sarcolemmal (s) 
channel, whose structure has been delineated, and a putative channel 
in the inner mitochondrial membrane, the mKATP channel.27 Although 
the mKATP channel has been characterized pharmacologically in cells 
and in isolated lipid bilayers, it has not been cloned, and its exact 
molecular structure has not been fully elucidated.28 In fact, the very 
existence of the mKATP channel has been questioned8,29 and, thus, is a 
matter of considerable controversy. 
Cardioprotection by drugs believed to be KATP channel openers is 
well established. Nineteen years ago, cromakalim and pinacidil,30 and 
subsequently other KATP channel openers,31 were found to be protective 
in perfused rat hearts. Initially, it was believed that sKATP channel 
opening was responsible for this cardioprotection because it shortened 
the action potential duration, thereby reducing Ca2+ entry to the 
cytosol. However, it was shown later that cardioprotection was 
preserved in conditions without shortening of the action potential 
duration32 and that selective pharmacological sKATP channel inhibition 
had no effect on infarct size after IR or on preconditioning.33 
Garlid et al34 provided the first evidence to support a role for the 
mKATP channel in cardioprotection. They found that mKATP channels in 
lipid bilayers were 1000 to 2000 times more sensitive to diazoxide 
than were sKATP channels. Furthermore, diazoxide, at low 
concentrations that did not activate the sKATP channel, had a 
pronounced cardioprotective effect in isolated hearts. This effect was 
abolished by 5-HD and glibenclamide, suggesting that the mKATP 
channel, rather than the sKATP channel, may be responsible for this 
cardioprotection. 
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However, it is still unclear whether mKATP channel opening acts 
as a trigger or a distal effector in pharmacologic preconditioning, or 
both. As a trigger, mKATP channels would have to open under 
physiological conditions before ischemia and lead to activation of 
downstream signaling pathways of preconditioning. In contrast, if 
mKATP channel opening was an effector of preconditioning, these 
signaling pathways would contribute to mKATP channel opening during 
energetically less physiological conditions such as IR and, thus, afford 
protection. 
IR impairs mitochondrial function through an alteration of Δψm, 
electron transport, and increased ROS production. Pharmacological 
KATP channel opening inhibited ischemia-induced depletion of high-
energy phosphates, which was abolished by glibenclamide; it was 
proposed that mKATP channel opening may partially restore the Δψm, 
allowing further extrusion of H+, forming a more favorable 
electrochemical gradient for ATP synthesis.35 
How Does mKATP Channel Opening Affect Mitochondrial 
Function? 
Despite all this evidence, there is considerable disagreement as 
to the exact mechanism by which mKATP channel opening alters 
mitochondrial function. On one side, Marban and colleagues have 
argued that opening of any mitochondrial K+ channel in the inner 
mitochondrial membrane, including the mKATP channel, would tend to 
dissipate Δψm established by the proton pump.3,12 This dissipation 
would accelerate electron transfer by the ETC, lead to a net oxidation 
in the mitochondrial matrix, and “uncouple” oxidative phosphorylation. 
Consequently, autofluorescent measurements of the mitochondrial 
redox state have become an increasingly popular tool to assess mKATP 
channel opening in isolated myocytes.12,36–38 
Alternatively, the concept of uncoupling by mKATP channel 
opening is opposed by Garlid and colleagues,2 who contend that the 
critical effect resulting from mKATP channel opening is the regulation 
and maintenance of mitochondrial matrix volume.39 Decreased Δψm, 
for instance, during ischemia, would lead to decreased mitochondrial 
matrix volume, resulting in decreased and less efficient electron 
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transport and ATP synthesis.40 Increased K+ conductance by mKATP 
channel opening and concomitant uptake of weak acids and water by 
osmotic forces34 would counteract this volume decrease and help 
maintain a constant matrix volume, permitting a more efficient energy 
transfer between mitochondria and cellular ATPases.41,42 
Garlid and colleagues2 further argue that a K+ influx sufficient to 
cause significant uncoupling would cause massive matrix swelling and 
rupture the mitochondrial inner membrane under physiological 
conditions. Therefore, at least under energetically more physiological 
conditions, uncoupling by mKATP channel opening would not occur, and 
the fact that accelerated electron transport and net oxidation by mKATP 
channel openers was observed in several studies may merely be 
attributable to artificial study conditions.2,43 Our findings agree with 
those of Garlid et al2: experiments in intact beating hearts14 have 
revealed dose-dependent increases in reduced nicotinamide adenine 
dinucleotide fluorescence by pinacidil and decreases in oxidized flavin 
adenine dinucleotide fluorescence by diazoxide. This reduced 
mitochondrial redox state could be produced by attenuated electron 
transport secondary to inhibition of complex I or II of the ETC, 
respectively, rather than accelerated electron transport, as would have 
been expected for mKATP channel opening. Furthermore, these 
inhibitory effects were not prevented by mKATP channel blockers. 
In the present study, by measuring the rate of O2 consumption 
in isolated cardiac mitochondria, we used a different approach to 
complement and confirm these findings. Under energetically more 
physiological conditions with sufficient substrate as electron donor, O2 
as electron acceptor, and ADP to allow oxidative phosphorylation, we 
found diazoxide and pinacidil to differentially attenuate electron 
transport at complexes I and II, respectively, independent of mKATP 
channel opening; in contrast, accelerated respiration as an indication 
of mKATP channel opening could not be observed under these 
conditions (Fig. 3). 
Inhibitory Side Effects of KATP Channel Openers 
The selective inhibition of complex I and complex II of the ETC 
by pinacidil and diazoxide, respectively, confirms earlier44–46 and more 
recent7,8,10,11,39,47 reports of mKATP channel–independent inhibitory 
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effects of these drugs on the ETC in mitochondria of various cell types. 
In fact, it was known long ago that the hydrophobic sites of the 
mitochondrial ETC are sensitive to hydrophobic agents48; this may 
offer a relatively simple explanation for the otherwise paradoxical 
observation of ETC inhibition by putative mKATP channel openers. 
Interestingly, we find very similar results for NS1619, a mitochondrial 
Ca2+ sensitive K+ channel opener, that also causes a mild attenuation 
of mitochondrial respiration under energetically more physiological 
conditions, whereas respiration is accelerated under energetically less 
physiological conditions23; similarly, the acceleration, but not 
attenuation, was blocked by the mKCa channel blocker paxilline. 
Mitochondrial Energetic State is an Important 
Determinant of KATP Channel Opening 
Energetically less physiological “state 4” conditions impede 
mitochondrial respiration indirectly by inhibiting protons from 
reentering the mitochondrial matrix via ATP synthase and, thus, 
increasing Δψm, either because of a shortage of ADP or, as achieved in 
this study, by pharmacological ATP synthase inhibition. Under 
conditions of increased Δψm, any form of ion leakage, as with 
pharmacological uncoupling or mKATP channel opening, would be 
expected to result in a robust increase in electron transport and O2 
consumption. Under conditions of pharmacological ATP synthase 
inhibition, ADP phosphorylation to ATP, and, therefore, the ATP/ADP 
ratio, are decreased (Table 2), which would be expected to favor 
opening of the mKATP channels even more, because they are normally 
kept closed by a high ATP/ADP ratio. 
Indeed, in this isolated mitochondrial model, a mild, indirect 
attenuation of mitochondrial respiration by ATP synthase inhibition was 
sufficient to profoundly change the observed effects of the two mKATP 
channel openers. Under these conditions, both mKATP channel openers 
accelerated mitochondrial respiration. Reversal of their effects by two 
different KATP channel antagonists is consistent with mKATP channel 
opening. So, within the same model, and under identical conditions 
except for an altered energetic state, we were able to change the 
effect of known and putative49 mKATP channel openers from differential 
ETC attenuation and slowed respiration toward accelerated respiration 
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by mKATP channel opening (Fig. 4). These findings emphasize the 
crucial importance of a lower mitochondrial energy state for mKATP 
channels to open, and they help to explain previous observations of 
increased mitochondrial oxidation, that is, respiration, by mKATP 
openers such as diazoxide12 or volatile anesthetics37 in isolated resting 
myocytes that were performed or cultured in substrate-free 
solutions.2,43 
Drawing any further conclusions from these findings remains 
challenging. On the one hand, in favor of a pharmacological approach,2 
one can conclude that mKATP openers indeed open mKATP channels 
under both energetically more physiological and energetically less 
physiological conditions, and that mKATP channel opening simply has 
only a negligible effect on mitochondrial respiration under physiological 
conditions. As an alternative conclusion, one can conclude that KATP 
channel openers are ineffective under physiological conditions if KATP 
channel opening is primarily a function of the cell's energetic state, 
that is, its ATP/ADP ratio, especially in the vicinity of the channels, and 
mKATP channel openers may act, for instance, by reducing the ATP 
affinity of the channel. 
Although we cannot safely rule out such possibilities as the 
presence of restricted spaces preventing instantaneous equilibration of 
ATP, ADP, or mKATP channel openers near the channels in vivo or in our 
model, this latter conclusion would go along with the notion of other 
investigators: the less physiological, the earlier KATP channels open, 
and any potential opener36,50,51 shifts this opening to more 
physiological states and, in this way, “sensitizes” or “primes” the 
channels to open earlier and to a greater extent under energetically 
less physiological conditions such as ischemia. 
A Further Lack of Specificity of KATP Channel Openers 
and Antagonists 
Conclusions about mKATP channel involvement derived from 
pharmacological studies are further complicated by recent reports11,52–
54 that diazoxide mildly uncouples respiration even in the absence of 
K+, raising the possibility of mKATP channel–independent iono- and 
protonophoric effects of putative mKATP channel openers that may be 
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(partly) responsible for their cardioprotective effect. Similar findings 
have recently been reported for the mKCa channel opener NS1619.55 
In addition, the specificities of not only openers, but also of 
antagonists of mKATP channels and other intracellular signaling 
components, for instance, PKCε,56 are now more and more questioned. 
For example, it was recently suggested that 5-HD, as a fatty acid, 
could be converted to 5-HD-CoA in the presence of CoA, ATP, and fatty 
acyl CoA synthetase.7–9 5-HD could then be further metabolized and 
serve as a substrate that feeds electrons into the ETC at the level of 
coenzyme Q, thus providing a bypass for ETC sites that are attenuated 
by lipophilic drugs such as KATP channel openers7,39 or volatile 
anesthetics.6,57 KATP channel–independent effects have also been 
described for glibenclamide. For example, it inhibits carnitine 
palmitoyltransferase activity58 and, at higher concentrations, Cl− 
channels,59 whereas permeabilization of the mitochondrial membrane 
to Cl– may contribute to mitochondrial depolarization.60 
Alternative explanations of cardioprotection by KATP channel 
openers also include ETC inhibition of complex I61 or II,62 and the 
activation of the adenine nucleotide translocase,63possibly even as part 
of a multiprotein complex that contains complex II and ATP 
synthase.64 All of these findings clearly reinforce the notion that any 
conclusion as to the mechanisms of action of a certain drug has to rely 
on its pharmacological specificity. In this particular case, an observed 
effect associated with administration of a putative mKATP channel 
opener or its blockade by a potential antagonist does not necessarily 
furnish direct evidence of mKATP channel involvement (for a more 
detailed review, see Hanley and Daut43). We need to be aware of the 
“pleiotropic” character of these drugs, and, ideally, we have to confirm 
any findings by using more than one model as well as a variety of 
chemically different drugs with different chemical profiles to 
strengthen our conclusions. 
Conclusion 
In summary, the finding of differential effects of mKATP channel 
openers on mitochondrial function under different energetic conditions 
underscores and reemphasizes the importance of the chosen 
experimental model and its physiological condition when studying 
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mitochondria and helps explain some of the contradictory data in 
literature. 
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